CAJ | 학술논문

背景：同位素标记相对和绝对定量(Isobaric tags for relative and absolute quantitation，iTRAQ)质谱分析技术依据串联质谱中信号离子表达质荷比峰值的不同来研究相关对应蛋白质的信息。目的：建立急性脊髓损大鼠模型，观察其脑脊液差异蛋白谱，从微观分子水平研究急性脊髓损伤后继发性损伤的机制及有效治疗方法。方法：建立SD大鼠急性脊髓损伤模型，取脑脊液应用iTRAQ技术鉴定SD大鼠急性脊髓损伤后脑脊液的差异蛋白质。结果与结论：共鉴定蛋白数722个，差异表达蛋白107个：下调的差异蛋白有63个，上调的差异蛋白数是44个。其中相关神经再生的差异蛋白19个：上调14个，下调5个；调节神经再生的差异蛋白7个。实验中检测到的多种差异蛋白及表达明显的神经再生因子可能作为急性脊髓损伤的生物标记物或可能作为临床管理监测急性脊髓损伤的损伤进程、靶向治疗及评估疗效的强有力证据。
배경：동위소표기상대화절대정량(Isobaric tags for relative and absolute quantitation，iTRAQ)질보분석기술의거천련질보중신호리자표체질하비봉치적불동래연구상관대응단백질적신식。목적：건립급성척수손대서모형，관찰기뇌척액차이단백보，종미관분자수평연구급성척수손상후계발성손상적궤제급유효치료방법。방법：건립SD대서급성척수손상모형，취뇌척액응용iTRAQ기술감정SD대서급성척수손상후뇌척액적차이단백질。결과여결론：공감정단백수722개，차이표체단백107개：하조적차이단백유63개，상조적차이단백수시44개。기중상관신경재생적차이단백19개：상조14개，하조5개；조절신경재생적차이단백7개。실험중검측도적다충차이단백급표체명현적신경재생인자가능작위급성척수손상적생물표기물혹가능작위림상관리감측급성척수손상적손상진정、파향치료급평고료효적강유력증거。
BACKGROUND:Isobaric tags for relative and absolute quantitation (iTRAQ) mass spectrometry technology studys the information of relevant protein according to the ion signal shows different mass-to-charge ratio in the tandem mass spectrometry analysis. OBJECTIVE:To establish the protein spectrum of differential proteins in cerebrospinal fluid of acute spinal cord injury rat model, study the secondary injury mechanism and find an effective method of treating acute spinal cord injury from molecular level. METHODS:Acute spinal cord injury was produced in Sprague-Dawley rats and iTRAQ technology was applied to analyze the differential proteins in cerebrospinal fluid of acute spinal cord injury rat model. RESULTS AND CONCLUSION:Total 722 proteins have been identified in this study, including 107 differentialy expressed proteins, 63 downregulated proteins and 44 upregulated proteins. There were 19 proteins related to neurogenesis, including 14 up-regulation proteins and 5 down-regulation proteins. Seven proteins contributed to the regulation of neurogenesis. The differential proteins and growth factor identified in this study can be taken as the biomarkers of acute spinal cord injury or indicators of clinical monitoring of the progression, target treatment and efficacy assessment after acute spinal cord injury.